Inscripta Acquires Infinome Biosciences and Sestina Bio
January 18, 2023
Inscripta, a genome engineering company based in Pleasanton, California, has acquired synthetic biology firms Infinome Biosciences and Sestina Bio to accelerate its capabilities in sustainable biomanufacturing. The acquisitions integrate Infinome's GenoScaler strain-engineering platform and Sestina's data-driven scale-up strain design to advance Inscripta's commercialization of bio-manufactured products for industrial and consumer markets.
- Buyers
- Inscripta
- Targets
- Infinome Biosciences, Sestina Bio
- Industry
- Biotechnology
- Location
- California, United States
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
Quintara Biosciences Acquires Laragen Sanger Sequencing Business from Transnetyx
September 15, 2025
Biotechnology
Quintara Biosciences has completed the acquisition of the Laragen Sanger Sequencing business (formerly operated by Transnetyx), effective September 15, 2025. The purchase preserves local operations and customer service in Los Angeles while expanding Quintara’s California sequencing footprint and capabilities.
-
10x Genomics to Acquire Scale Biosciences
August 7, 2025
Healthcare Services
10x Genomics, Inc. has signed a definitive agreement to acquire Scale Biosciences, Inc., a single-cell analysis company. The deal is intended to expand 10x’s Chromium platform with Scale’s key inventions and technologies and broaden access to scalable single-cell analysis for researchers worldwide.
-
Standard BioTools Acquires Sengenics from Summa Equity
November 21, 2024
Biotechnology
Standard BioTools Inc. has acquired Sengenics Corporation Pte Ltd, a Summa Equity portfolio company, to broaden its proteomics and antibody‑profiling capabilities. The deal will integrate Sengenics' KREX™ immunoproteomics and i-OME™ Discovery platform with Standard BioTools' SomaScan/proteomics offerings to enhance biomarker discovery and accelerate drug development.
-
Intus Bio Acquires Pattern Genomics
June 28, 2023
Biotechnology
Intus Biosciences (Intus Bio) has acquired Pattern Genomics, integrating Pattern's advanced genomic analysis and machine learning tools into Intus Bio's Titan-1 microbiome assay and analysis platform. The acquisition, supported by investor Connecticut Innovations, brings Pattern Genomics' founder Daniel Fasulo into Intus Bio as Head of IT and Bioinformatics to accelerate capability expansion and biomarker discovery across healthcare and pharmaceutical end markets.
-
Twist Bioscience Acquires iGenomX
June 30, 2021
Biotechnology
Twist Bioscience acquired iGenomX, a developer of high-throughput multiplex NGS library preparation tools, to expand its NGS workflow capabilities and accelerate customer conversion from microarray genotyping to sequencing-based genotyping. The deal consideration was $35 million (combination of cash and Twist stock, plus up to $5 million contingent stock), and Twist expects modest near-term financial impact with incremental revenue from the acquired business in fiscal 2023.
-
insitro Acquires Haystack Sciences
October 22, 2020
Biotechnology
insitro has acquired Haystack Sciences to integrate Haystack’s DNA-encoded library (DEL) technology and nDexer platform into insitro’s machine-learning-driven drug discovery efforts. The acquisition expands insitro’s small-molecule design and high-throughput chemistry capabilities to accelerate predictive model-driven therapeutics discovery; financial terms were not disclosed.
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.